Ad is loading...
JCVSX
Price
$37.35
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

JCVSX vs VVIAX

Header iconJCVSX vs VVIAX Comparison
Open Charts JCVSX vs VVIAXBanner chart's image
JHancock Classic Value R2
Price$37.35
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
JCVSX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JCVSX vs. VVIAX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JCVSX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. JCVSX (1.25B). VVIAX pays higher dividends than JCVSX: VVIAX (2.36) vs JCVSX (1.11). JCVSX was incepted earlier than VVIAX: JCVSX (13 years) vs VVIAX (24 years). JCVSX is a more actively managed with annual turnover of: 24.00 vs. VVIAX (10.00). JCVSX has a lower initial minimum investment than VVIAX: JCVSX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. JCVSX (11.76). VVIAX return over 5 years is better than : 53.09 vs. JCVSX (18.48).
JCVSXVVIAXJCVSX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years24 years-
Gain YTD7.82319.67240%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.25B184B1%
Annual Yield % from dividends1.112.3647%
Returns for 1 year11.7626.0945%
Returns for 3 years-4.4224.77-18%
Returns for 5 years18.4853.0935%
Returns for 10 years51.51112.2646%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics